ENDPOINTS

Hunger-suppressing biotech Aardvark raises $94M in IPO

Aardvark Therapeutics, a biotech looking to address hunger rather than appetite for metabolic diseases, will go public on Thursday in a $94 million debut on Nasdaq. The San Diego-based biotech joins fellow obesity drug developer ...

Feb 13, 2025 - 11:14
 0
Hunger-suppressing biotech Aardvark raises $94M in IPO
Aardvark Therapeutics, a biotech looking to address hunger rather than appetite for metabolic diseases, will go public on Thursday in a $94 million debut on Nasdaq. The San Diego-based biotech joins fellow obesity drug developer ...
Read More

Tags:

Previous Article

Oil firms' plans for net-zero oil extraction labelled as 'PR spiel'

Next Article

Green Humour by Rohan Chakravarty on Mumbai’s worsening AQI and new Ferris wheel...

Related Posts

Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial

Boehringer Ingelheim touts success in second Phase 3 lu...

Feb 10, 2025  0

Hims’ Super Bowl ad has drawn criticism from lawmakers — and now Novo Nordisk

Hims’ Super Bowl ad has drawn criticism from lawmakers ...

Feb 10, 2025  0

Kaiser Permanente calls on FDA and Congress to firm up accelerated approval requirements

Kaiser Permanente calls on FDA and Congress to firm up ...

Feb 12, 2025  0